Pulse Biosciences(NASDAQ) PLSE

Pulse Biosciences makes tools to treat heart rhythm problems. Its technology uses quick electrical pulses to clear targeted cells. These tools help doctors treat patients without using extreme heat.

Medical Tools for Clearer Paths

• Vybrance Electrode System: Needle-based tool used to remove soft tissue without heat; accounts for 100% of revenue for the six months ended June 30, 2026.
• Cardiac Catheter System: Thin tube designed to treat irregular heartbeats by clearing specific heart cells; currently undergoing clinical trials.
• Cardiac Surgical Clamp: Tool used during surgery to block faulty electrical signals in the heart; received Breakthrough Device Designation from the FDA.
• nPulse Console: Software-driven platform that delivers electrical pulses to various medical devices and disposables.

Strategic Shift to the Heart

• Abandoned dermatological product sales in Sept. 2022 to focus on cardiac care and atrial fibrillation.
• Announced a strategic realignment in March 2026 to accelerate the development of heart rhythm devices.
• Received FDA Breakthrough Device Designation for the cardiac surgery system in July 2024.
• Initiated a pivotal clinical study for the cardiac catheter in April 2026.
• Recorded the first commercial sales of the Vybrance system in the third quarter of 2025.

Zapping Cells Without Heat

The proprietary technology delivers pulses lasting less than a millionth of a second to kill cells without heat damage. This method protects nearby tissue like nerves, blood vessels, and collagen that traditional thermal treatments might harm.

A Look at the Books

• Product revenue was $835,000 for the six months ended June 30, 2026.
• Research and development costs rose $7.2 million for the six months ended June 30, 2026.
• Net loss reached $43.2 million for the six-month period ended June 30, 2026.
• Cash and cash equivalents totaled $101.6 million as of June 30, 2026.
• Net proceeds from stock sales reached $46.8 million during the first half of 2026.

Bottom Line

Pulse Biosciences transitioned from skin treatments to focus on heart rhythm technology. Its development of non-thermal tools seeks to provide safer options for complex surgical procedures.